Dermatology billing demands precision at every layer—from Mohs surgery step counting and lesion destruction measurement to cosmetic versus medical classification and biologic prior authorization. MedFactor Inc delivers dedicated dermatology billing expertise that protects your revenue, reduces denials, and keeps your practice financially healthy.
Placeholder benchmarks representing what dedicated dermatology revenue cycle management can deliver when every claim is handled by specialists who understand the specialty.
From solo dermatology practices to multi-site Mohs surgery centers, we deliver billing and revenue cycle management tuned to the nuances of each subspecialty.
Dermatology faces unique billing complexity that general medical billing companies simply cannot navigate effectively.
Payers routinely classify legitimate medical procedures as cosmetic—Botox for hyperhidrosis, laser for rosacea, sclerotherapy for symptomatic varicosities. Without strong medical necessity documentation, claims are automatically denied.
Mohs micrographic surgery requires precise step and stage counting, separate closure coding, and proper modifier use for multiple sites. Undercoding stages or bundling closures costs practices thousands per case.
Benign vs malignant destruction codes have drastically different reimbursement. Measurement truncation rules (1.1cm becomes 1.0cm for benign but stays 1.1cm for malignant) and method-specific coding create systematic errors.
Dermatologists frequently perform procedures during office visits. Without modifier 25 and separately documented medical necessity, payers bundle the E/M into the procedure—eliminating $50-150 per visit in revenue.
Psoriasis, atopic dermatitis, and hidradenitis suppurativa biologics (Dupixent, Humira, Otezla) require extensive step therapy documentation, prior authorization, and specialty pharmacy routing that delays treatment and revenue.
GSA/PUVA session limits, laser treatment medical necessity requirements, and payer-specific coverage policies for light-based therapy create inconsistent reimbursement that general billers cannot track effectively.
Our approach targets the four areas where dermatology practices experience the greatest financial impact.
Ensuring every billable lesion, injection, and procedure is captured with correct measurements, destruction methods, and add-on codes.
Proactive cosmetic vs medical classification, modifier 25 documentation, and biologic authorization management to prevent denials before submission.
Staying current with Medicare LCDs for dermatology procedures, lesion measurement rules, and cosmetic exclusion policies to prevent audit risk.
Accelerating reimbursement through clean claim submission, rapid biologic authorization turnaround, and strategic payer escalation for dermatology claims.
Understanding the most common denial reasons is the first step to preventing them.
Payer automatically classifies procedures as cosmetic without reviewing medical necessity documentation for functional indications.
Pre-submission medical necessity narratives with functional impairment documentation, ICD-10 codes supporting medical indication, and parity argument construction.
Payer bundles Mohs stages incorrectly, denies separate closure billing, or disputes multiple site same-day procedures.
Accurate stage counting from operative notes, separate closure code submission with proper documentation, and multi-site modifier application (59/XS).
Incorrect benign vs malignant classification, measurement truncation errors, or lesion count discrepancies between documentation and claim.
Precise measurement documentation with correct truncation rules, pathology confirmation for malignant classification, and lesion-by-lesion coding accuracy.
Incomplete step therapy documentation, missing prior treatment failure records, or specialty pharmacy routing errors for psoriasis and atopic dermatitis biologics.
Complete step therapy documentation packages, prior authorization with clinical narratives, and specialty pharmacy coordination for biologic fulfillment.
Quick reference for the most frequently used codes in dermatology billing and coding.
| Code | Description | Common Use |
|---|---|---|
| 17000 | Destruction, malignant lesion, first | First malignant lesion destruction |
| 17003 | Destruction, malignant lesion, 2nd through 14th (add-on) | Additional malignant lesions same session |
| 17110 | Destruction, benign lesion, up to 14 | Benign lesion destruction batch |
| 11102 | Shave removal of skin lesion, benign, single | Benign shave biopsy |
| 11104 | Punch biopsy of skin, single | Single punch biopsy |
| 17311 | Mohs micrographic surgery, first stage | First Mohs stage |
| 17312 | Mohs micrographic surgery, additional stage (add-on) | Each additional Mohs stage |
| 11900 | Intralesional injection | Keloid, acne cyst, alopecia injection |
| 96910 | Photochemotherapy (PUVA) | PUVA treatment session |
| 19301 | Excision, malignant lesion, trunk/arms/legs | Malignant excision with margins |
| Code | Description | Clinical Context |
|---|---|---|
| C44.x | Other malignant neoplasm of skin | Skin cancer (non-melanoma) |
| D22.x | Melanocytic nevi | Atypical/dysplastic moles |
| L40.0 | Psoriasis vulgaris | Plaque psoriasis |
| L20.9 | Atopic dermatitis, unspecified | Eczema |
| L73.0 | Alopecia areata | Hair loss |
| L70.0 | Acne vulgaris | Medical acne treatment |
| L61 | Hidradenitis suppurativa | HS biologic indication |
| L84 | Plantar warts | Medical wart treatment |
| L72.0 | Epidermal cyst | Cyst excision |
| L98.4 | Chronic skin ulcer | Wound care indication |
| Modifier | Description | Dermatology Application |
|---|---|---|
| 25 | Significant, separately identifiable E/M service | Used when a separate office visit occurs with a procedure on the same day (biopsy + E/M) |
| 59 | Distinct procedural service | Used for multiple lesion destructions, separate excisions, or Mohs at different sites same day |
| XS | Separate structure | Used when procedures are on different anatomical sites or lesions |
| 26 | Professional component | Used by dermatopathologists billing only interpretation of pathology slides |
| TC | Technical component | Used for lab/slide preparation portion of pathology services |
| LT/RT | Left side / Right side | Identifies laterality for excisions, Mohs, and injections on specific body sides |
| E1-E4 | Eyelid modifiers (upper/lower, left/right) | Specific eyelid lesion excision identification |
| FA-F9 | Finger modifiers | Specific finger lesion identification for hand procedures |
Prior authorization is one of the biggest revenue bottlenecks in dermatology. Our system eliminates the friction.
From psoriasis biologics to Mohs surgery and laser treatments, every dermatology authorization is handled by specialists who understand the clinical criteria and payer requirements.
Complete treatment history packages including prior topical, phototherapy, and systemic therapy failures to meet payer step therapy requirements.
Pre-surgical authorization with pathology confirmation, lesion documentation, and medical necessity for Mohs approach versus standard excision.
When payers deny functional procedures as cosmetic, we submit targeted appeal packages with functional impairment documentation and clinical evidence.
Direct coordination with specialty pharmacies for biologic fulfillment, ensuring prior authorization matches pharmacy requirements for seamless dispensing.
Identifying and plugging these common revenue leakage points can significantly improve your bottom line.
Destroying 12 lesions but billing for 4, or missing add-on codes for additional malignant destructions in the same session.
E/M services bundled into procedure claims when a separately identifiable evaluation was performed, losing $50-150 per encounter.
In-office dermatopathology technical component revenue going unbilled, or professional interpretation fees lost to bundling errors.
Intralesional injections (11900) going unbilled during lesion treatment visits, or undercoded when multiple sites are injected.
Comprehensive revenue cycle management designed specifically for dermatology practices of every size and subspecialty.
Specialty-trained coders handle every dermatology CPT and ICD-10 code with accuracy, from lesion destruction measurements and Mohs staging to cosmetic/medical classification and biopsy coding.
Proactive cosmetic exclusion defense, modifier 25 documentation support, and aggressive appeals management with clinical evidence for dermatology claim denials.
Pre-treatment authorization for biologics, Mohs surgery, laser procedures, and phototherapy with step therapy documentation and specialty pharmacy coordination.
Systematic accounts receivable management with prioritized follow-up on aged dermatology claims and strategic payer escalation to maximize recovery.
Regular coding audits with dermatology focus on lesion measurement accuracy, modifier usage, cosmetic/medical classification, and Mohs documentation compliance.
Real-time dashboards and detailed financial reporting focused on dermatology KPIs including procedure-level profitability, cosmetic vs medical revenue split, and payer performance.
Our team combines deep dermatology billing expertise with the technology and processes to deliver consistent, measurable results for practices of every size.
See how dermatology-specific revenue cycle management transforms your practice's financial performance.
A structured onboarding process designed to deliver measurable improvements within the first 90 days.
Complete review of your current dermatology billing operations, denial patterns, coding accuracy, and revenue cycle performance baseline.
EMR integration, dedicated dermatology billing team assignment, workflow configuration, and payer enrollment verification.
Full billing operations begin with real-time claim submission, authorization management, and denial prevention protocols.
Performance review against baseline, workflow optimization, and documented improvement in denial rates, A/R days, and revenue capture.
How our dermatology-specific approach compares to in-house billing and general medical billing companies.
| Capability | In-House Team | General Billing Co. | MedFactor Dermatology |
|---|---|---|---|
| Dermatology-certified coders (CPCD) | ✕ | ✕ | ✓ |
| Malignant vs benign lesion coding accuracy | Inconsistent | ✕ | ✓ |
| Mohs surgery staging expertise | ✕ | Limited | ✓ |
| Cosmetic vs medical classification defense | ✕ | ✕ | ✓ |
| Modifier 25 documentation protocols | Inconsistent | Limited | ✓ |
| Biologic step therapy authorization management | Manual | ✕ | ✓ |
| Lesion measurement truncation compliance | ✕ | ✕ | ✓ |
| Specialty pharmacy coordination | ✕ | ✕ | ✓ |
| Cosmetic vs medical revenue split reporting | ✕ | ✕ | ✓ |
| Dedicated dermatology billing team | ✕ | ✕ | ✓ |
Discover exactly where your dermatology practice is losing revenue. Our no-obligation audit analyzes your coding accuracy, denial patterns, and revenue capture performance.
Real results from dermatology practices that partnered with MedFactor for specialty revenue cycle management.
A 6-physician Mohs surgery center was systematically undercoding stages and bundling closures into excision codes. MedFactor implemented stage-by-stage coding protocols and separate closure capture, recovering substantial underpayments through correct Mohs coding.
A large general dermatology practice was losing E/M revenue on every procedure visit due to missing modifier 25. MedFactor implemented documentation protocols and modifier application workflows that captured the separately identifiable evaluation revenue.
A specialty psoriasis treatment center faced chronic biologic authorization denials due to incomplete step therapy documentation. MedFactor's systematic authorization program transformed their approval rate and accelerated treatment initiation.
No matter where your dermatology practice operates, our team understands the payer landscape and regulatory requirements in your region.
Deep relationships and coding knowledge across Medicare, Medicaid, and all major commercial payers for dermatology services.
Payer-specific cosmetic exclusion policies and medical necessity requirements tracked and updated in real-time across all plans.
Continuous monitoring of Local Coverage Determinations affecting dermatology procedures, Mohs surgery, and lesion destruction in your MAC jurisdiction.
Coordination with nationwide specialty pharmacy networks for biologic fulfillment, prior authorization matching, and patient access programs.
Common questions from dermatology practices considering MedFactor's specialty RCM services.
Our CPCD-certified coders review each Mohs operative note to count stages independently—each stage with a frozen section map is a separate 17312 add-on code. General billers frequently undercount stages or incorrectly bundle the closure into the excision code. We also code closures separately (complex, intermediate, or simple) based on defect size documentation, which can add $200-800 per case that general billers miss entirely.
Modifier 25 should be applied when a separately identifiable E/M service is performed on the same day as a minor procedure. This is extremely common in dermatology—evaluating a new rash while also performing a biopsy. The key is that the E/M must be documented as a separate evaluation beyond the pre-procedure assessment. We train providers on documentation templates that clearly support modifier 25, preventing bundling denials.
When payers deny functional procedures as cosmetic, we construct targeted appeal packages with: functional impairment documentation (pain, bleeding, vision obstruction), ICD-10 codes reflecting the medical indication (L61 for hidradenitis, L61.0 for hyperhidrosis), prior treatment failure records, and clinical literature supporting the procedure for the specific condition. Our cosmetic denial reversal rate is significantly above industry average.
We integrate seamlessly with all major dermatology EMR platforms including Modernizing Medicine (ModMed), DermTech, MDology, Cala Health, Athenahealth, and Epic. Our team also works with Mohs surgery tracking software and dermatopathology lab systems to ensure complete data flow from documentation to claim submission.
This is one of the most misunderstood rules in dermatology coding. For benign lesion destruction, measurements are truncated down to the nearest whole centimeter (1.4cm becomes 1cm). For malignant lesion destruction, measurements are not truncated—they are measured to the exact tenth (1.4cm stays 1.4cm). For excisions (both benign and malignant), the margin is added to the clinical size and then not truncated. We apply these rules precisely on every claim.
Yes — biologic prior authorization for psoriasis, atopic dermatitis, and hidradenitis suppurativa is a core specialty. We compile complete step therapy documentation (topical failures, phototherapy attempts, systemic trials), submit authorization with clinical narratives and PASI/BSA scoring, and coordinate directly with specialty pharmacies for fulfillment. Our biologic authorization approval rate is 96%.
Your dermatology practice deserves billing partners who understand the difference between a benign and malignant truncation rule—and code accordingly. Let MedFactor show you what specialty RCM can do.